TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Protalix ( (PLX) ) has issued an update.
On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request for a re-examination of the European Medicines Agency’s negative opinion on the proposed dosing regimen for Elfabrio, a treatment for Fabry disease. The existing marketing authorization for Elfabrio remains in effect while the re-examination is underway, highlighting the companies’ commitment to addressing the needs of the Fabry community.
The most recent analyst rating on (PLX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
Protalix’s overall stock score is driven by strong earnings call insights and positive technical indicators. Financial performance shows improvement, though leverage concerns persist. Valuation remains a moderate risk due to a high P/E ratio.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company has achieved FDA approval for proteins produced through this system and has partnered with Chiesi Farmaceutici S.p.A. for the global development of its second product, Elfabrio. Protalix’s pipeline includes products targeting established pharmaceutical markets, such as treatments for Gaucher disease and NETs-related diseases.
Average Trading Volume: 818,733
Technical Sentiment Signal: Buy
Current Market Cap: $189M
Learn more about PLX stock on TipRanks’ Stock Analysis page.